MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$73,127K
EPS
-$0.65
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2025-12-31
2025-09-30
2025-06-30
Collaboration revenue
0
0
0
4,015
In-process research and development
-
10,000
0
0
Research and development
59,885
50,770
49,193
40,451
General and administrative
18,250
12,091
10,945
10,042
Total operating expenses
78,135
72,861
60,138
50,493
Loss from operations
-78,135
-72,861
-60,138
-46,478
Interest income
5,008
2,961
2,681
3,081
Net loss
-73,127
-69,900
-57,457
-43,397
Basic EPS
-0.65
-0.736
-0.65
-0.5
Diluted EPS
-0.65
-0.736
-0.65
-0.5
Basic Average Shares
113,272,931
95,024,860
87,957,868
87,010,742
Diluted Average Shares
113,272,931
95,024,860
87,957,868
87,010,742
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$73,127K
(-68.51%↓ Y/Y)
Interest income
$5,008K
(62.54%↑ Y/Y)
Loss from operations
-$78,135K
(-68.11%↓ Y/Y)
Total operating
expenses
$78,135K
(54.74%↑ Y/Y)
Research and development
$59,885K
(48.04%↑ Y/Y)
General and
administrative
$18,250K
(81.74%↑ Y/Y)
Buy us a coffee
Immunome Inc. (IMNM)
Immunome Inc. (IMNM)